A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma-Reference-Cited by-同舟云学术

A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma

Published:2004-08-12 Issue:6 Volume:126 Page:792-798
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Cook G.,Clark R. E.,Morris T. C. M.,Robertson M.,Lucie N. P.,Anderson S.,Paul J.,Franklin I. M.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2004.05127.x/fullpdf

Reference17 articles.

1. VAD chemotherapy as remission induction for multiple myeloma;Anderson;British Journal of Cancer,1995

2. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation;Blade;British Journal of Haematology,1998

3. An analysis of which subgroups of multiple myeloma patients, divided according to beta-2 microglobulin and plasma cell labelling index, benefit from high dose versus conventional chemotherapy;Boccadoro;Haematologica,1999

4. High-dose therapy with haematopoietic stem-cell rescue for multiple myeloma;Child;New England Journal of Medicine,2003

5. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment;Clark;British Journal of Haematology,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline treatment for transplant‐eligible multiple myeloma: A 6474 patients network meta‐analysis;Hematological Oncology;2018-09-20

2. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management;Hematological Oncology;2015-06-15

3. Phase I Study to Determine the Maximal Tolerated Dose and Dose-Limiting Toxicities of Orally Administered Idarubicin in Dogs with Lymphoma;Journal of Veterinary Internal Medicine;2012-03-09

4. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma;Bone Marrow Transplantation;2010-06-21

5. Is there a role for 'modified VAD' in the treatment of multiple myeloma?;ecancermedicalscience;2010